GGHC
CYTK icon

Gilder Gagnon Howe & Co’s Cytokinetics CYTK Stock Holding History

Gilder Gagnon Howe & Co’s Portfolio CYTK Stock Details CYTK Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$34.1M Buy
400,245
+69,256
+21% +$4.97M 0.35% 77
2026
Q1 		$21.8M Sell
330,989
-54,831
-14% -$3.48M 0.26% 84
2025
Q4 		$24.5M Sell
385,820
-3,235
-0.8% -$201K 0.26% 86
2025
Q3 		$21.4M Buy
389,055
+197,940
+104% +$8.15M 0.22% 89
2025
Q2 		$6.31M Buy
191,115
+176,253
+1,186% +$6.13M 0.07% 131
2025
Q1 		$597K Buy
14,862
+2,970
+25% +$136K 0.01% 207
2024
Q4 		$559K Sell
11,892
-1,663
-12% -$86.4K 0.01% 229
2024
Q3 		$716K Sell
13,555
-275
-2% -$15.3K 0.01% 222
2024
Q2 		$749K Sell
13,830
-221
-2% -$13.3K 0.01% 216
2024
Q1 		$985K Sell
14,051
-12,294
-47% -$951K 0.01% 209
2023
Q4 		$2.2M Sell
26,345
-188
-0.7% -$6.81K 0.03% 175
2023
Q3 		$782K Buy
26,533
+69
+0.3% +$2.3K 0.01% 219
2023
Q2 		$863K Sell
26,464
-373
-1% -$13.8K 0.01% 232
2023
Q1 		$944K Sell
26,837
-483
-2% -$19.7K 0.02% 198
2022
Q4 		$1.25M Buy
27,320
+1,485
+6% +$63.9K 0.02% 191
2022
Q3 		$1.25M Buy
+25,835
New +$1.24M 0.02% 190

Other funds holding CYTK

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $11.1B AUM 207.82% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Gilder Gagnon Howe & Co's CYTK Position: Q2 2026 in Review

Gilder Gagnon Howe & Co increased its Cytokinetics (CYTK) stake by 21% in Q2 2026, buying an estimated $4.97M and bringing the position to 400,245 shares worth $34.1M. The position accounts for 0.35% of the portfolio, ranked #77.

Gilder Gagnon Howe & Co first reported a position in CYTK in Q3 2022 and has held it in 16 quarters since. 482 funds tracked by Wall St. Rank hold CYTK as of Q2 2026.

  • Gilder Gagnon Howe & Co held 400,245 shares of Cytokinetics worth $34.1M as of Q2 2026.
  • Gilder Gagnon Howe & Co bought 69,256 Cytokinetics shares in Q2 2026, an estimated $4.97M.
  • Cytokinetics made up 0.35% of Gilder Gagnon Howe & Co's portfolio in Q2 2026, its #77 holding.
  • Gilder Gagnon Howe & Co first reported a position in Cytokinetics in Q3 2022 and has held it in 16 quarters since.
  • 482 funds tracked by Wall St. Rank held Cytokinetics as of Q2 2026.

Based on Gilder Gagnon Howe & Co's 13F filing for Q2 2026, filed 14 Aug 2026.